open access
Current evidence of rivaroxaban in cancer-associated thrombosis
Affiliations- Department of Cardiac and Vascular Surgery Division of Vascular Surgery Medical University of Gdańsk, ul. Dębinki 7, 80-952 Gdańsk, Poland
open access
Abstract
Patients with cancer have a high risk of developing cancer-associated thrombosis (CAT). Current guidelines suggest
preferential use of low molecular weight heparins (LMWH) in CAT. The real-world data show that compliance with
recommended LMWH therapy in cancer patients is low. Many patients discontinue injectable anticoagulants
prematurely, in some cases even after a month, despite a high recurrence rate in this population. In recent
years an increasing number of cancer patients are treated with direct oral anticoagulants, mainly rivaroxaban.
Recent data confirming the safety and efficacy of rivaroxaban are starting to emerge and support the growing
trend of using direct oral anticoagulants in cancer patients. If positive results of the recently completed SELECT-D
trial are confirmed in the upcoming trials and registries of CALLISTO project, the guidelines for the treatment
of CAT will have to be revised in favour of DOAC use in cancer-associated thrombosis.
Abstract
Patients with cancer have a high risk of developing cancer-associated thrombosis (CAT). Current guidelines suggest
preferential use of low molecular weight heparins (LMWH) in CAT. The real-world data show that compliance with
recommended LMWH therapy in cancer patients is low. Many patients discontinue injectable anticoagulants
prematurely, in some cases even after a month, despite a high recurrence rate in this population. In recent
years an increasing number of cancer patients are treated with direct oral anticoagulants, mainly rivaroxaban.
Recent data confirming the safety and efficacy of rivaroxaban are starting to emerge and support the growing
trend of using direct oral anticoagulants in cancer patients. If positive results of the recently completed SELECT-D
trial are confirmed in the upcoming trials and registries of CALLISTO project, the guidelines for the treatment
of CAT will have to be revised in favour of DOAC use in cancer-associated thrombosis.
Keywords
venous thromboembolism, cancer, cancer-associated thrombosis, direct oral anticoagulants, low molecular weight heparins, vitamin K antagonists
About this articleTitle
Current evidence of rivaroxaban in cancer-associated thrombosis
Journal
Issue
Pages
98-103
Published online
2018-10-25
Page views
831
Article views/downloads
882
DOI
Bibliographic record
Acta Angiologica 2018;24(3):98-103.
Keywords
venous thromboembolism
cancer
cancer-associated thrombosis
direct oral anticoagulants
low molecular weight heparins
vitamin K antagonists
Authors
Grzegorz Wojciech Halena
Agnieszka Kulik